Kevin Ingham (pictured) has joined CDMO AGC Biologics as General Manager / Site Head in Seattle, where he will oversee the strategic development and operational excellence in clinical and commercial biologics production at the site.
Ingham brings with him more than 18 years of leadership experience in the biotechnology and manufacturing industry, most recently as Site Head/Executive Director of Drug Product Manufacturing for Switzerland-based Roche. His past experience also includes roles at Genentech.
In his new role, Ingham will support the continuous growth of the site, while working with colleagues across AGC Biologics global network of facilities to bring new biopharmaceuticals to market.
Meanwhile, Tony Fraij will oversee strategic development and operational excellence in large-scale C> production as General Manager / Site Head at the company’s new Longmont site in Colorado.
Together with the Heidelberg and Milan sites, the Longmont facility will become an integral part of AGC Biologics’ end-to-end cell and gene therapy CDMO services, which currently includes plasmid DNA, viral vectors and cell therapies. Fraij has over 20 years of industry experience, having led operations at Boehringer Ingelheim, Sandoz, Novartis, and AveXis.